Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15667928 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1468566 | 0.89 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL14632098 | 0.89 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL967296 | 0.89 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL968086 | 0.89 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1290745 | 0.88 | SLC6A4 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL14224174 | 0.87 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1060281 | 0.87 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1877085 | 0.87 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL27957684 | 0.85 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| EP-2925737-A1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | Zafgen, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014071369-A1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-1945606-A1 | ALKYLCARBAMOYL NAPHTHALENYLOXY- OCTENOYLHYDROXYAMIDE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PREPARATION THEREOF | Korea Research Institute of Chemical Technology (KR) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007052938-A1 | ALKYLCARBAMOYL NAPHTHALENYLOXY- OCTENOYLHYDROXYAMIDE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | SLC6A2 119/4885SLC6A4 40/4885SLC6A3 14/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | SLC6A2 119/4885SLC6A4 40/4885SLC6A3 14/4885 |
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | SLC6A2 4321/4885SLC6A4 4238/4885SLC6A3 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.